{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:43:30Z","timestamp":1792799010564,"version":"4.5.0"},"reference-count":31,"publisher":"BMJ","license":[{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006701","name":"Umm Al-Qura University","doi-asserted-by":"publisher","award":["no grant number"],"award-info":[{"award-number":["no grant number"]}],"id":[{"id":"10.13039\/501100006701","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Manchester National Institute for Health Research Manchester Biomedical Research Centre","award":["IS-BRC-1215-20007"],"award-info":[{"award-number":["IS-BRC-1215-20007"]}]},{"name":"Yorkshire Cancer Research","award":["award reference L403"],"award-info":[{"award-number":["award reference L403"]}],"id":[{"id":"https:\/\/ror.org\/02cddnn97","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Thorax"],"accepted":{"date-parts":[[2025,12,19]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Lung cancer screening is effective for people at higher risk of the disease, but there is no international consensus on eligibility criteria. Some programmes use risk factors; others use multivariable risk scores, which might target an older, more comorbid population and thus limit life years gained. In this study, we compare frailty, comorbidities and overall survival between different eligible populations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Participants aged 55\u201374 years undergoing lung cancer risk assessment in the Yorkshire Lung Screening Trial were analysed, comparing those who met the US Preventive Services Task Force 2021 lung cancer screening criteria (USPSTF\n                      <jats:sub>2021<\/jats:sub>\n                      ) criteria against established risk-based criteria currently used in screening protocols (Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial risk model (PLCO\n                      <jats:sub>m2012<\/jats:sub>\n                      ) \u22651.51%, used internationally, and the Liverpool Lung Project risk model (version 2) (LLP\n                      <jats:sub>v2<\/jats:sub>\n                      ) \u22652.5%, used in the UK), examining the number of individuals with frailty and comorbidities selected by each approach. In addition, risk score thresholds were set to select equivalent numbers of people screened compared with USPSTF\n                      <jats:sub>2021<\/jats:sub>\n                      . Data recorded in primary care prior to randomisation were retrospectively extracted to allow calculation of the electronic Frailty Index (eFI) and an overall comorbidity count. Frailty, comorbidity counts and 3-year overall survival were compared between these various populations.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 11\u2009994 individuals aged 55\u201374 undergoing risk assessment, 3502 were eligible by USPSTF\n                      <jats:sub>2021<\/jats:sub>\n                      , 3139 by PLCO\n                      <jats:sub>m2012<\/jats:sub>\n                      \u22651.51%\u2009and 3957 by LLP\n                      <jats:sub>v2<\/jats:sub>\n                      \u22652.5%. The proportion of individuals with moderate\/severe frailty was lower for the USPSTF\n                      <jats:sub>2021<\/jats:sub>\n                      population (10.6%) compared with PLCO\n                      <jats:sub>m2012<\/jats:sub>\n                      \u22651.51% (13.1%, adjusted p=0.0777) and LLP\n                      <jats:sub>v2<\/jats:sub>\n                      \u22652.5% (13.4%, adjusted p=0.0272). The USPSTF\n                      <jats:sub>2021<\/jats:sub>\n                      identified significantly fewer individuals with multiple comorbidities (30.8%) than the PLCO\n                      <jats:sub>m2012<\/jats:sub>\n                      (36.1%, adjusted p=0.0033) and the LLP\n                      <jats:sub>v2<\/jats:sub>\n                      (37.3%, adjusted p=0.0001).\n                    <\/jats:p>\n                    <jats:p>\n                      When compared in equivalent populations, both PLCO\n                      <jats:sub>m2012<\/jats:sub>\n                      with a threshold of 1.32%, and LLP\n                      <jats:sub>v2<\/jats:sub>\n                      with a threshold of 2.92%, had a higher proportion of people both with moderate\/severe frailty (12.6%, adjusted p=0.221\u2009and 14.0%, adjusted p=0.0067 respectively) and multiple comorbidities (35.1%, adjusted p=0.0211\u2009and 38.5%, adjusted p&lt;0.0001 respectively) than USPSTF\n                      <jats:sub>2021<\/jats:sub>\n                      .\n                    <\/jats:p>\n                    <jats:p>There were no apparent differences in 3-year overall survival between the eligible populations overlapping 95% CIs across risk groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      These data suggest that currently used risk models identify populations with a small increase in moderate\/severe frailty and multimorbidity compared to the USPSTF\n                      <jats:sub>2021<\/jats:sub>\n                      criteria, but there is no evidence to suggest that this results in differences in 3-year overall survival.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/thorax-2024-222487","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T18:20:33Z","timestamp":1769538033000},"page":"thorax-2024-222487","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Frailty, comorbidity and survival comparisons between populations eligible for screening according to risk factor versus risk score criteria: results from the Yorkshire Lung Screening Trial"],"prefix":"10.1136","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7893-0123","authenticated-orcid":false,"given":"Anas","family":"Almatrafi","sequence":"first","affiliation":[{"name":"Department of Epidemiology and Medical Statistics, College of Public Health and Health Informatics, Umm Al-Qura University, Makkah, Saudi Arabia"},{"name":"University of Leeds Leeds Institute of Health Sciences, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhian","family":"Gabe","sequence":"additional","affiliation":[{"name":"Centre for Evaluation and Methods, Wolfson Institute of Population Health, Queen Mary University of London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca J","family":"Beeken","sequence":"additional","affiliation":[{"name":"University of Leeds Leeds Institute of Health Sciences, Leeds, UK"},{"name":"Department of Behavioural Science and Health, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard D","family":"Neal","sequence":"additional","affiliation":[{"name":"University of Leeds Leeds Institute of Health Sciences, Leeds, UK"},{"name":"University of Exeter, Exeter, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Clegg","sequence":"additional","affiliation":[{"name":"Academic Unit of Ageing and Stroke Research, University of Leeds, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate E","family":"Best","sequence":"additional","affiliation":[{"name":"Academic Unit of Ageing and Stroke Research, University of Leeds, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Relton","sequence":"additional","affiliation":[{"name":"University of Leeds Leeds Institute of Health Sciences, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martel","family":"Brown","sequence":"additional","affiliation":[{"name":"Leeds Office of Data Analytics, Leeds Health and Care Partnership, NHS West Yorkshire Integrated Care Board, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8542-1749","authenticated-orcid":false,"given":"Hui Zhen","family":"Tam","sequence":"additional","affiliation":[{"name":"Centre for Evaluation and Methods, Wolfson Institute of Population Health, Queen Mary University of London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Vulkan","sequence":"additional","affiliation":[{"name":"Centre for Evaluation and Methods, Wolfson Institute of Population Health, Queen Mary University of London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Hancock","sequence":"additional","affiliation":[{"name":"University of Leeds Leeds Institute of Health Sciences, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8941-4813","authenticated-orcid":false,"given":"Philip A","family":"Crosbie","sequence":"additional","affiliation":[{"name":"Division of Immunology, Immunity to Infection & Respiratory Medicine, The University of Manchester Faculty of Biology Medicine and Health, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8157-0803","authenticated-orcid":false,"given":"Matthew E J","family":"Callister","sequence":"additional","affiliation":[{"name":"University of Leeds Leeds Institute of Health Sciences, Leeds, UK"},{"name":"Department of Respiratory Medicine, Leeds Teaching Hospitals NHS Trust, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,1,27]]},"reference":[{"key":"2026022610203315000_thorax-2024-222487v2.1","doi-asserted-by":"publisher","DOI":"10.3322\/CAAC.21834"},{"key":"2026022610203315000_thorax-2024-222487v2.2","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2020-216555"},{"key":"2026022610203315000_thorax-2024-222487v2.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1102873"},{"key":"2026022610203315000_thorax-2024-222487v2.4","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz117"},{"key":"2026022610203315000_thorax-2024-222487v2.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911793"},{"key":"2026022610203315000_thorax-2024-222487v2.6","doi-asserted-by":"publisher","DOI":"10.7326\/M13-2771."},{"key":"2026022610203315000_thorax-2024-222487v2.7","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.1117"},{"key":"2026022610203315000_thorax-2024-222487v2.8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00590-8"},{"key":"2026022610203315000_thorax-2024-222487v2.9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001764","article-title":"Evaluation of the lung cancer risks at which to screen ever- and never-smokers: screening rules applied to the PLCO and NLST cohorts","volume":"11","author":"Tammem\u00e4gi","year":"2014","journal-title":"PLoS Med"},{"key":"2026022610203315000_thorax-2024-222487v2.10","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6604158"},{"key":"2026022610203315000_thorax-2024-222487v2.11","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.lungcan.2021.04.005","article-title":"Selection of individuals for lung cancer screening based on risk prediction model performance and economic factors - The Ontario experience","volume":"156","author":"Tammem\u00e4gi","year":"2021","journal-title":"Lung Cancer (Auckl)"},{"key":"2026022610203315000_thorax-2024-222487v2.12","unstructured":"BC Gov News . BC cancer launches lung-screening program-news release. 2022. Available: https:\/\/news.gov.bc.ca\/releases\/2022HLTH0145-000816 [Accessed 10 Jun 2024]."},{"key":"2026022610203315000_thorax-2024-222487v2.13","unstructured":"NHS England . Standard protocol prepared for the targeted lung health checks programme. 2022. Available: https:\/\/www.england.nhs.uk\/publication\/targeted-screening-for-lung-cancer\/ [Accessed 14 Feb 2025]."},{"key":"2026022610203315000_thorax-2024-222487v2.14","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.chest.2021.06.066","article-title":"Addressing Sex Disparities in Lung Cancer Screening Eligibility: USPSTF vs PLCOm2012 Criteria","volume":"161","author":"Pasquinelli","year":"2022","journal-title":"Chest"},{"key":"2026022610203315000_thorax-2024-222487v2.15","doi-asserted-by":"crossref","first-page":"8880","DOI":"10.1002\/cam4.5638","article-title":"Comparison of the sensitivity of different criteria to select lung cancer patients for screening in a cohort of German patients","volume":"12","author":"Walter","year":"2023","journal-title":"Cancer Med"},{"key":"2026022610203315000_thorax-2024-222487v2.16","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1093\/jnci\/djaa013","article-title":"Disparities of National Lung Cancer Screening Guidelines in the US Population","volume":"112","author":"Han","year":"2020","journal-title":"J Natl Cancer Inst"},{"key":"2026022610203315000_thorax-2024-222487v2.17","doi-asserted-by":"publisher","DOI":"10.7326\/M17-2701"},{"key":"2026022610203315000_thorax-2024-222487v2.18","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djz164"},{"key":"2026022610203315000_thorax-2024-222487v2.19","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2020-214626"},{"key":"2026022610203315000_thorax-2024-222487v2.20","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2021-217142"},{"key":"2026022610203315000_thorax-2024-222487v2.21","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.lungcan.2020.07.027","article-title":"Baseline Results of the West London lung cancer screening pilot study \u2013 Impact of mobile scanners and dual risk model utilisation","volume":"148","author":"Bartlett","year":"2020","journal-title":"Lung Cancer (Auckl)"},{"key":"2026022610203315000_thorax-2024-222487v2.22","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00483-2022","article-title":"Participation in community-based lung cancer screening: the Yorkshire Lung Screening Trial","volume":"60","author":"Crosbie","year":"2022","journal-title":"Eur Respir J"},{"key":"2026022610203315000_thorax-2024-222487v2.23","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-037075","article-title":"Yorkshire Lung Screening Trial (YLST): protocol for a randomised controlled trial to evaluate invitation to community-based low-dose CT screening for lung cancer versus usual care in a targeted population at risk","volume":"10","author":"Crosbie","year":"2020","journal-title":"BMJ Open"},{"key":"2026022610203315000_thorax-2024-222487v2.24","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afw039"},{"key":"2026022610203315000_thorax-2024-222487v2.25","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1177\/09691413251315087","article-title":"Impact of frailty and comorbidity on initial response to lung cancer screening invitation and low-dose CT screening uptake: Findings from the Yorkshire Lung Screening Trial","volume":"32","author":"Almatrafi","year":"2025","journal-title":"J Med Screen"},{"key":"2026022610203315000_thorax-2024-222487v2.26","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(87)90171-8"},{"key":"2026022610203315000_thorax-2024-222487v2.27","doi-asserted-by":"publisher","DOI":"10.7326\/M19-1263"},{"key":"2026022610203315000_thorax-2024-222487v2.28","doi-asserted-by":"crossref","first-page":"243","DOI":"10.21037\/tlcr.2018.06.03","article-title":"Selecting lung cancer screenees using risk prediction models-where do we go from here","volume":"7","author":"Tammem\u00e4gi","year":"2018","journal-title":"Transl Lung Cancer Res"},{"key":"2026022610203315000_thorax-2024-222487v2.29","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1001\/jamaoncol.2016.6416","article-title":"Lung Cancer Screening With Low-Dose Computed Tomography in the United States-2010 to 2015","volume":"3","author":"Jemal","year":"2017","journal-title":"JAMA Oncol"},{"key":"2026022610203315000_thorax-2024-222487v2.30","doi-asserted-by":"crossref","first-page":"4341","DOI":"10.1002\/cncr.29677","article-title":"Comorbidities, smoking status, and life expectancy among individuals eligible for lung cancer screening","volume":"121","author":"Howard","year":"2015","journal-title":"Cancer"},{"key":"2026022610203315000_thorax-2024-222487v2.31","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1093\/eurpub\/ckz052","article-title":"Lung cancer survival and comorbidities in lung cancer screening participants of the Gda\u0144sk screening cohort","volume":"29","author":"Ostrowski","year":"2019","journal-title":"Eur J Public Health"}],"container-title":["Thorax"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/thorax-2024-222487","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T18:20:39Z","timestamp":1772130039000},"score":1,"resource":{"primary":{"URL":"https:\/\/thorax.bmj.com\/lookup\/doi\/10.1136\/thorax-2024-222487"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,27]]},"references-count":31,"alternative-id":["10.1136\/thorax-2024-222487"],"URL":"https:\/\/doi.org\/10.1136\/thorax-2024-222487","relation":{},"ISSN":["0040-6376","1468-3296"],"issn-type":[{"value":"0040-6376","type":"print"},{"value":"1468-3296","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,27]]}}}